Michael E. Weinblatt
Brigham and Women's Hospital · 534 works · 54,265 citations · h-index 99
Top works
- Principal components analysis corrects for stratification in genome-wide association studies
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
- Etanercept Therapy in Rheumatoid Arthritis
- Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
- The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.
- Rheumatoid arthritis
- Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
- Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis
- Methotrexate for Rheumatoid Arthritis
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial
- Reduced joint counts in rheumatoid arthritis clinical trials
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- Two independent alleles at 6q23 associated with risk of rheumatoid arthritis
- Long‐term prospective trial of low‐dose methotrexate in rheumatoid arthritis
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
- Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison